Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response

Background Preclinical results showing therapeutic effect and low toxicity of metronomic chemotherapy with cyclophosphamide (Cy) + celecoxib (Cel) for mammary tumors encouraged its translation to the clinic for treating advanced breast cancer patients (ABCP). Patients and methods A single-arm, mo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Perroud, Herman A, Alasino, Carlos María , Rico, María José, Mainetti, Leandro Ernesto, Queralt, Francisco , Pezzotto, Stella Maris, Rozados, Viviana R., Scharovsky, O. Graciela
Formato:	article artículo acceptedVersion
Lenguaje:	Inglés
Publicado:	Springer 2018
Materias:	Angiogenesis Biomarkers Cyclophosphamide Celecoxib Metronomic chemotherapy
Acceso en línea:	http://hdl.handle.net/2133/11096 http://hdl.handle.net/2133/11096
Aporte de:	Repositorio Hipermedial de la Universidad Nacional de Rosario (UNR) de Universidad Nacional de Rosario

Ejemplares similares

Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients
por: Perroud, Herman A, et al.
Publicado: (2018)

Association between baseline VEGF/sVEGFR-2 and VEGF/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer
por: Perroud, Herman A, et al.
Publicado: (2018)

Comparative Effectiveness of Two Metronomic Chemotherapy Schedules. Our Experience in the Preclinical Field
por: Rico, María José, et al.
Publicado: (2018)

The Immune Response and the Therapeutic Effect of Metronomic Chemotherapy With Cyclophosphamide
por: Rozados, Viviana R., et al.
Publicado: (2012)

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
por: Perroud, Herman A, et al.
Publicado: (2018)

Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
por: Rozados, Viviana R., et al.
Publicado: (2012)

Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas
por: Mainetti, Leandro Ernesto, et al.
Publicado: (2018)

Achievements and challenges in the use of metronomics for the treatment of breast cancer
por: Scharovsky, O. Graciela, et al.
Publicado: (2020)

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan
por: Bouche, Gauthier, et al.
Publicado: (2018)

Inmunomodulación y antiangiogénesis en la terapéutica oncológica. De la investigación básica a la clínica
por: Scharovsky, O. Graciela, et al.
Publicado: (2012)

Métodos para la identificación del Celecoxib
por: Teixeira Primo, Fabián, et al.
Publicado: (2005)

Sustainable chemotherapy schedules
por: Barrea, Andrés Alberto, et al.
Publicado: (2021)

Sustainable chemotherapy schedules
por: Barrea, Andrés Alberto, et al.
Publicado: (2021)

Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model
por: Rico, María José, et al.
Publicado: (2012)

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
Publicado: (1999)

A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma
por: Blajman, C., et al.

The use of cyclophosphamide as an enhancer of the vaccine against foot-and-mouth disease
por: Portiansky, Enrique Leo, et al.
Publicado: (1996)

A Novel Synergistic Combination of Cyclophosphamide and Gene Transfer of Interleukin-12 Eradicates Colorectal Carcinoma in Mice
por: Malvicini, Mariana, et al.
Publicado: (2012)

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models
por: Rico, María José, et al.
Publicado: (2018)

Comment on ‘‘Coxibs Refocus Attention on the Cardiovascular Risks of Non-Aspirin NSAIDs’’
por: Urtasun, Martin A., et al.
Publicado: (2017)

Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia.
por: Bonella, Belen Maria, et al.
Publicado: (2017)

Hyponatremia induced by high-dose cyclophosphamide therapy: a retrospective cohort study Cyclophosphamide and Hyponatremia.
por: Bonella, Belen Maria, et al.
Publicado: (2017)

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide
por: Zacarías Fluck, M.F., et al.

The understanding of information about oral chemotherapy treatment among outpatients at a University Hospital in Ceará, Brazil
por: Pereira, Ana G. da S., et al.
Publicado: (2010)

Modulation of IL-10/IL-10R expression by mafosfamide, a derivative of 4-hydroxycyclophosphamide, in a rat B-cell lymphoma
por: Rico, María José, et al.
Publicado: (2013)

Protective and immunostimulating activity of a low dose of cyclophosphamide in the experimental infection of mice with foot-and-mouth disease virus
por: Portiansky, Enrique Leo, et al.
Publicado: (1989)

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide
por: Salatino, Mariana, et al.
Publicado: (2012)

Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide
por: Casas, Adriana Gabriela, et al.
Publicado: (1997)

Potentiation of the 5-aminolevulinic acid-based photodynamic therapy with cyclophosphamide
por: Casas, A., et al.

Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice.
por: Casas, Adriana Gabriela, et al.
Publicado: (1997)

Metabolic changes in the heme pathway driven by cyclophosphamide treatment in mice.
por: Casas, A., et al.

Preparation, characterization and in-vitro evaluation of sunflower oil-Tween 80-Glycerol-based microemulsion formulation of a BCS class-II Drug
por: Kamila, Madan M., et al.
Publicado: (2009)

Simultaneous determination of cyclophosphamide and Ifosfamide in plasma using SPE-HPLC-UV method
por: Martins, Isarita, et al.
Publicado: (2009)

A Symmetrical Dirhenium(I) Complex with 4,4’’-Azobis(2,2’-bipyridine) as a Bridging Ligand: Synthesis, Physicochemical Properties and Applications in Detection of Biologically Relevant Thiols and in Chemotherapy for Bone Cancer
por: Abate, Pedro Oscar, et al.
Publicado: (2020)

Addition of vasopressin synthetic analogue [V<sup>4</sup>Q<sup>5</sup>]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
por: Garona, Juan, et al.
Publicado: (2016)

Cyclophosphamide and its metabolite acrolein. Some studies on their porphyrinogenic action in 17 day old chick embryo
por: Cochón, Adriana Cristina
Publicado: (1992)

Cyclophosphamide and its metabolite acrolein. Some studies on their porphyrinogenic action in 17 day old chick embryo
por: Cochón, A.C., et al.

Cyclophosphamide and its metabolite acrolein. Some studies on their porphyrinogenic action in 17 day old chick embryo.
por: Cochón, Adriana Cristina, et al.
Publicado: (1992)

Cyclophosphamide and its metabolite acrolein. Some studies on their porphyrinogenic action in 17 day old chick embryo.
por: Cochón, A.C., et al.